Viewing nowOnglyza Tablet 2.5 mg (Saxagliptin Hydrate)
Saxagliptin Hydrate 2.64mg
Tablet · Prescription medication
AstraZeneca Korea Co., Ltd.

MFDS item code 201100374 · Approved 2011.01.24 · Insurance code 650700890
Improvement of glycemic control in type 2 diabetes mellitus
This medication helps patients with type 2 diabetes to achieve more effective blood sugar control by combining meal plans and exercise. It can be used alone or in combination with other medications. It significantly aids in blood sugar management, supporting the maintenance of a healthy lifestyle.
1. When administered as monotherapy, the recommended dose of this drug is 2.5mg or 5mg once daily. 2. When administered in combination therapy - For patients with no prior experience of antidiabetic drug treatment who do not achieve adequate glycemic control with monotherapy, the recommended dose of this drug when administered in combination with metformin is 5mg once daily. - For patients who do not achieve adequate glycemic control with metformin, a sulfonylurea, or a thiazolidinedione as monotherapy, the recommended dose of this drug when administered in combination is 2.5mg or 5mg once daily. - For patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, the recommended dose of this drug when administered in combination is 5mg once daily. - For patients who do not achieve adequate glycemic control with insulin therapy (insulin alone or in combination with metformin), the recommended dose of this drug when administered in combination is 5mg once daily. - For patients who do not achieve adequate glycemic control with combination therapy of metformin and dapagliflozin, the recommended dose of this drug when administered in combination is 5mg once daily. This drug may be administered regardless of meals and should not be cut or divided. Patients with renal impairment: - Patients with mild renal impairment (eGFR ≥45mL/min/1.73 m2): No dose adjustment is required. - Patients with moderate or severe renal impairment, or end-stage renal disease requiring hemodialysis (eGFR <45mL/min/1.73 m2): Administer 2.5mg once daily. This drug should be administered after hemodialysis and has not been studied in patients receiving peritoneal dialysis. Since dose adjustment may be required according to renal function, assessment of renal function is recommended before starting this drug and periodically during treatment. When administered in combination with a strong cytochrome P450 3A4/5 inhibitor: Administer 2.5mg once daily. (See section ‘5. Interactions’ under Precautions for Use.) When administered in combination with insulin or an insulin secretagogue (such as a sulfonylurea), a lower dose of insulin and the insulin secretagogue may be needed to minimize the risk of hypoglycemia.
This medication should not be administered to specific patients. Patients who have had severe allergic reactions or angioedema to this medication or other DPP-4 inhibitors should not take this medication. Additionally, it should not be administered to patients with type 1 diabetes or diabetic ketoacidosis. This medication contains lactose, therefore, patients with genetic disorders such as lactose intolerance, lactase deficiency, or glucose-galactose malabsorption should not use it. Caution is needed when this medication is taken with other hypoglycemic agents, as the risk of hypoglycemia may increase. Particularly, when used in combination with insulin or sulfonylureas, the dosages of these medications may need to be reduced to lower the risk of hypoglycemia. In patients with heart failure, especially those with severe heart failure, the experience with this medication is limited, thus it should be administered cautiously. Patients with a history of heart failure or significantly impaired renal function should be closely monitored for symptoms of heart failure, and if symptoms occur, medical personnel should be notified immediately. While taking this medication, patients should be closely monitored for signs and symptoms of pancreatitis, and if pancreatitis is suspected, the medication should be stopped immediately and appropriate treatment should be sought. As hypersensitivity reactions may occur, if symptoms like hives, facial swelling, or anaphylaxis appear, the medication should be stopped immediately, and a doctor should be consulted. Common side effects of this medication may include upper respiratory tract infections, urinary tract infections, headaches, sinusitis, abdominal pain, gastroenteritis, and vomiting. There is a possibility of hypoglycemia, therefore, especially when taken with insulin or sulfonylureas, blood sugar levels should be regularly checked and symptoms of hypoglycemia should be monitored. This medication should only be used during pregnancy when clearly necessary and should be administered cautiously during breastfeeding. It is not recommended for use in children as safety and effectiveness have not been established. Elderly patients should be cautious regarding dosage adjustments due to the possibility of impaired renal function. No special dosage adjustments are needed for patients with liver impairment. In case of overdose, there is no specific antidote, and general treatment should be initiated based on symptoms; some can be removed by hemodialysis. This medication should be kept out of the reach of children and stored in its original container to prevent deterioration or misuse. Caution is also needed as symptoms like drowsiness may occur when driving or operating machinery.
Anaphylaxis, angioedema, acute pancreatitis, lymphocytopenia, hypoglycemia, headache, sinusitis, abdominal pain, gastroenteritis, vomiting, peripheral edema, urticaria, facial edema, tuberculosis, Salmonella sepsis, joint pain accompanied by severity and disability, bullous pemphigoid, rash, itching, dizziness, vertigo, paresthesia, dyspnea, pneumonia, hyperglycemia, diabetic ketoacidosis, leg fracture, arthritis, kidney stones, pyelonephritis, heart failure, sleep disorders, uterine bleeding, glaucoma, non-Hodgkin lymphoma, malignant liver neoplasm, malignant thyroid neoplasm, malignant brain neoplasm, lung carcinoma, viral infection, myocardial infarction, subarachnoid hemorrhage, febrile neutropenia, nasal polyps, chest discomfort, leg pain, fatigue, chest pain, generalized edema, altered temperature sensation, asthenia, edema, polyneuropathy, gait abnormalities, neuropathy, neuralgia, facial paralysis, increased sputum, cold, hemoptysis, bronchitis, rhinitis, asthma, rhinorrhea, emphysema, unspecified lipid metabolism disorder, increased triglycerides, weight loss, weight gain, hypertriglyceridemia, hyperlipidemia, dyslipidemia, dehydration, joint pain, musculoskeletal chest pain, myopathy, back pain, generalized pain, sciatica, acanthosis nigricans, eczema, skin disease, burns, cystitis, acute kidney failure, dysuria, painful urination, neurogenic bladder, nocturia, hypertension, cardiomegaly, insomnia, depression, acute stress response, anxiety, drowsiness, amenorrhea, vulvitis, vaginitis, menopausal symptoms, shingles, parasitic infection, palpitations, arrhythmia, tinnitus, soft tissue inflammation, taste changes, laceration, joint dislocation, diarrhea, hypotension, diabetic retinopathy
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to protect it from air and moisture. The recommended storage temperature is room temperature between 1-degree and 30-degrees Celsius.
Light yellow, biconvex, round, film-coated tablet
28 tablets (14 tablets/PTP × 2)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.